316 related articles for article (PubMed ID: 23021240)
1. Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.
Das SK; Sarkar S; Dash R; Dent P; Wang XY; Sarkar D; Fisher PB
Adv Cancer Res; 2012; 115():1-38. PubMed ID: 23021240
[TBL] [Abstract][Full Text] [Related]
2. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy.
Sarkar D; Su ZZ; Fisher PB
Cell Cycle; 2006 Jul; 5(14):1531-6. PubMed ID: 16861924
[TBL] [Abstract][Full Text] [Related]
3. Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.
Emdad L; Das SK; Wang XY; Sarkar D; Fisher PB
J Cell Physiol; 2018 Aug; 233(8):5684-5695. PubMed ID: 29278667
[TBL] [Abstract][Full Text] [Related]
4. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
5. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.
Greco A; Di Benedetto A; Howard CM; Kelly S; Nande R; Dementieva Y; Miranda M; Brunetti A; Salvatore M; Claudio L; Sarkar D; Dent P; Curiel DT; Fisher PB; Claudio PP
Mol Ther; 2010 Feb; 18(2):295-306. PubMed ID: 19888195
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention gene therapy (CGT): novel combinatorial approach for preventing and treating pancreatic cancer.
Sarkar S; Azab BM; Das SK; Quinn BA; Shen X; Dash R; Emdad L; Thomas S; Dasgupta S; Su ZZ; Wang XY; Sarkar D; Fisher PB
Curr Mol Med; 2013 Aug; 13(7):1140-59. PubMed ID: 23157679
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus.
Sarkar S; Azab B; Quinn BA; Shen X; Dent P; Klibanov AL; Emdad L; Das SK; Sarkar D; Fisher PB
Curr Mol Med; 2014 Jan; 14(1):125-40. PubMed ID: 24236457
[TBL] [Abstract][Full Text] [Related]
8. Cancer gene therapy with oncolytic adenoviruses.
Guse K; Hemminki A
J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
[TBL] [Abstract][Full Text] [Related]
9. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.
Sarkar S; Quinn BA; Shen XN; Dash R; Das SK; Emdad L; Klibanov AL; Wang XY; Pellecchia M; Sarkar D; Fisher PB
Oncotarget; 2015 May; 6(13):10712-27. PubMed ID: 25926554
[TBL] [Abstract][Full Text] [Related]
10. Armed replicating adenoviruses for cancer virotherapy.
Cody JJ; Douglas JT
Cancer Gene Ther; 2009 Jun; 16(6):473-88. PubMed ID: 19197323
[TBL] [Abstract][Full Text] [Related]
11. Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy.
Jiang G; Zhang L; Xin Y; Pei DS; Wei ZP; Liu YQ; Zheng JN
Acta Oncol; 2012 Mar; 51(3):285-92. PubMed ID: 21995527
[TBL] [Abstract][Full Text] [Related]
12. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
13. Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine, mda-7/IL-24: not insurmountable therapeutic problems.
Sarkar D; Dent P; Curiel DT; Fisher PB
Cancer Biol Ther; 2008 Jan; 7(1):109-12. PubMed ID: 18277093
[TBL] [Abstract][Full Text] [Related]
14. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells.
Dash R; Dmitriev I; Su ZZ; Bhutia SK; Azab B; Vozhilla N; Yacoub A; Dent P; Curiel DT; Sarkar D; Fisher PB
Cancer Gene Ther; 2010 Jul; 17(7):447-56. PubMed ID: 20150932
[TBL] [Abstract][Full Text] [Related]
15. Selectively replicating adenoviruses for oncolytic therapy.
Yoon TK; Shichinohe T; Laquerre S; Kasahara N
Curr Cancer Drug Targets; 2001 Aug; 1(2):85-107. PubMed ID: 12188883
[TBL] [Abstract][Full Text] [Related]
16. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7.
Lebedeva IV; Su ZZ; Sarkar D; Fisher PB
Semin Cancer Biol; 2003 Apr; 13(2):169-78. PubMed ID: 12654260
[TBL] [Abstract][Full Text] [Related]
17. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.
Robson T; Worthington J; McKeown SR; Hirst DG
Technol Cancer Res Treat; 2005 Aug; 4(4):343-61. PubMed ID: 16029055
[TBL] [Abstract][Full Text] [Related]
18. Engineering regulatory elements for conditionally-replicative adeno-viruses.
Haviv YS; Curiel DT
Curr Gene Ther; 2003 Aug; 3(4):357-85. PubMed ID: 12871022
[TBL] [Abstract][Full Text] [Related]
19. Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24.
Gao P; Sun X; Chen X; Wang Y; Foster BA; Subjeck J; Fisher PB; Wang XY
Cancer Res; 2008 May; 68(10):3890-8. PubMed ID: 18483274
[TBL] [Abstract][Full Text] [Related]
20. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Hamed HA; Das SK; Sokhi UK; Park MA; Cruickshanks N; Archer K; Ogretmen B; Grant S; Sarkar D; Fisher PB; Dent P
Cancer Biol Ther; 2013 Nov; 14(11):1039-49. PubMed ID: 24025359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
